ClinicalTrials.Veeva

Find clinical trials for Non-Hodgkin Lymphoma in Cincinnati, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma
B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Leukemia
B-Cell Chronic Lymphocytic Leukemia
Lymphoid Leukemia
Mantle-Cell Lymphoma

Non-Hodgkin Lymphoma trials near Cincinnati, OH, USA:

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracyc...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)

Phase 3

Novartis
Novartis

Cincinnati, Ohio, United States and 66 other locations

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non...

Enrolling
Refractory B-Cell Non-Hodgkin Lymphoma
B Cell Lymphoma
Drug: Cyclophosphamide
Genetic: CB-010

Phase 1

Caribou Biosciences

Cincinnati, Ohio, United States of America and 29 other locations

A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma (iMATRIX GLO)

ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature B-cell non...

Enrolling
Mature B-Cell Non-Hodgkin Lymphoma
Drug: Ifosfamide
Drug: Glofitamab

Phase 1, Phase 2

Roche
Roche

Cincinnati, Ohio, United States and 21 other locations

Study of IMPT-314 in R/R Aggressive B-cell NHL

This is a Phase 1/2, multi-center, open-label study evaluating the safety and efficacy of IMPT-314, a bispecific chimeric antigen receptor (CAR) targ...

Enrolling
Relapsed Non-Hodgkin Lymphoma
Refractory Non-Hodgkin Lymphoma
Drug: IMPT-314

Phase 1, Phase 2

ImmPACT Bio

Cincinnati, Ohio, United States and 19 other locations

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)

lymphoblastic leukemia (ALL) or relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (NHL).As of October 2022, no furt...

Enrolling
Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Biological: Brexucabtagene Autoleucel (KTE-X19)
Drug: Fludarabine

Phase 1, Phase 2

Gilead Sciences
Gilead Sciences

Cincinnati, Ohio, United States and 36 other locations

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies (ELiPSE-1)

ELiPSE-1 is a Phase 1, multi-center, dose-finding study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CNTY-101 in participant...

Enrolling
Aggressive Non-Hodgkin Lymphoma
Indolent Non-Hodgkin Lymphoma
Biological: IL-2
Biological: CNTY-101

Phase 1

Century Therapeutics

Cincinnati, Ohio, United States and 12 other locations

Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab

The most common types of mature B-cell lymphomas (MBLs) in children are Burkitt lymphoma (BL) and diffuse large B-cell lymphoma...

Enrolling
Non-hodgkin Lymphoma
Drug: Epcoritamab

Phase 1

Genmab
Genmab

Cincinnati, Ohio, United States and 39 other locations

Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma. (MAGNIFY)

Follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) are distinct histologic types of B-...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Rituximab
Drug: Lenalidomide

Phase 3

Celgene
Celgene

Cincinnati, Ohio, United States and 125 other locations

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun)

safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in participants with selected B-cell malignancies (types of non-...

Enrolling
Non-Hodgkin Lymphoma
Drug: Mosunetuzumab (Cohorts D-E)
Drug: Tocilizumab

Phase 2

Genentech
Genentech

Cincinnati, Ohio, United States and 57 other locations

A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLL

This is a Phase 1, open-label, multicenter study. This will be the first-in-human clinical study for ONO-7018 and will be conducted in two phases: a...

Enrolling
Lymphoma, Non-Hodgkin
Leukemia, Lymphocytic, Chronic, B-Cell
Drug: ONO-7018

Phase 1

Ono Pharmaceuticals
Ono Pharmaceuticals

Cincinnati, Ohio, United States and 9 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems